News
ACIU
2.655
+0.95%
0.025
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
NASDAQ · 4d ago
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
NASDAQ · 09/14 15:14
Weekly Report: what happened at ACIU last week (0907-0911)?
Weekly Report · 09/14 09:30
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
NASDAQ · 09/07 13:28
Weekly Report: what happened at ACIU last week (0831-0904)?
Weekly Report · 09/07 09:28
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
NASDAQ · 09/03 15:49
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
NASDAQ · 09/03 15:43
Here's Why You Should Add RNTX Stock to Your Portfolio Now
NASDAQ · 09/03 15:01
AC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to Board
TipRanks · 09/03 11:28
AC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in Focus
TipRanks · 09/02 16:31
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
NASDAQ · 09/01 13:05
Weekly Report: what happened at ACIU last week (0824-0828)?
Weekly Report · 08/31 09:30
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
NASDAQ · 08/27 14:57
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
NASDAQ · 08/27 13:42
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 08/27 12:05
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
NASDAQ · 08/26 16:29
Weekly Report: what happened at ACIU last week (0817-0821)?
Weekly Report · 08/24 09:30
Analysts Offer Insights on Healthcare Companies: AC Immune SA (ACIU) and Gilead Sciences (GILD)
TipRanks · 08/21 14:30
Stifel’s Thomas Shrader Reiterates Buy on AC Immune, Citing Diversified Neuroscience Pipeline, Promising NLRP3 Data, and Strong Cash Runway
TipRanks · 08/21 10:55
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline
Benzinga · 08/20 16:32
More
Webull provides a variety of real-time ACIU stock news. You can receive the latest news about AC Immune through multiple platforms. This information may help you make smarter investment decisions.
About ACIU
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.